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In Brief
Different dosages of an RNA-binding protein result in human neurological diseases of corresponding severities.
INTRODUCTION
Decades of human and mouse genetic studies have taught us that neurons are intolerant of significant alterations in protein abundance. Doubling a protein's levels, as in the case of chromosomal duplications, or halving it, as in the case of haploinsufficiency, can lead to neurological disorders ranging from autism to Alzheimer's disease (Chartier-Harlin et al., 2004; La Cognata et al., 2017; Ramocki et al., 2009; Rovelet-Lecrux et al., 2006; Sleegers et al., 2006) . That such large changes should prove detrimental to neurons is not surprising, but some studies have suggested that more modest alterations in protein levels can also be problematic (Gennarino et al., 2015a (Gennarino et al., , 2015b Xie et al., 2017) . Yet the molecular mechanisms that allow the brain to achieve precise control of protein levels are not well understood, and not much research attention has been given to the possibility that changes in posttranscriptional regulation (Fukao and Fujiwara, 2017; Mata et al., 2005 ) might be connected to disease.
We became interested in the posttranscriptional regulation of ATAXIN1 (ATXN1), the protein whose mutation causes spinocerebellar ataxia type 1 (SCA1), after discovering that transgenic mice and flies overexpressing ATXN1 develop neurological degeneration reminiscent of SCA1 (Burright et al., 1995; Fernandez-Funez et al., 2000) . We found that ATXN1 is a target of PUMILIO1 (PUM1), a member of the PUMILIO/FBF (PUF) RNA-binding protein (RBP) family that is evolutionarily conserved from plants to humans (Gennarino et al., 2015b) . The PUF protein family is characterized by a highly conserved RNA-binding Pumilio homology domain (PUM-HD) consisting of eight tandem repeats that regulate specific mRNA targets posttranscriptionally, with or without the contribution of the microRNA machinery (Kedde et al., 2010; Miles et al., 2012) . Different studies have shown that Pum1 is an essential regulator of spermatogenesis in mice (Chen et al., 2012) and critical for differentiation of embryonic stem cells (Leeb et al., 2014; Spassov and Jurecic, 2003) , cell-cycle control (Kedde et al., 2010; Miles et al., 2012) , and genomic stability (Lee et al., 2016) . Drosophila pum mutants show sterility, behavioral defects, and neuronal hyperexcitability (Schweers et al., 2002) , and it was recently reported that RNAi-mediated knockdown of pum exacerbates seizures in flies bearing a gain-of-function mutation in the Drosophila voltage-gated sodium channel (Lin et al., 2017) .
The importance of PUM1 function in the mammalian brain, however, was not apparent until we found that Pum1-heterozygous mice develop a progressive ataxia and Purkinje cell degeneration that resembles what we see in SCA1 mice (Watase et al., 2002) , largely due to an increase in Atxn1 RNA and protein levels of about 30%-40% in the cerebellum (Gennarino et al., 2015b) . Pum1 null mice experience a roughly 50%-60% rise in Atxn1 levels and develop a more severe phenotype, with hyperactivity, developmental delay, smaller body size and weight, infertility, and shortened lifespan (Chen et al., 2012; Gennarino et al., 2015b) . Removing a copy of Pum1 in SCA1 mice accelerates their disease progression, whereas removing a copy of Atxn1 in Pum1-heterozygous mice rescues the cerebellar phenotypes by normalizing wild-type (WT) Atxn1 levels (Gennarino et al., 2015b) . Other features of the Pum1 nulls, such as hyperactivity, are not rescued after normalizing Atxn1 levels in Pum1 mutant mice, confirming the contributions of other Pum1 targets to the null phenotype.
These data led us to hypothesize that PUM1 insufficiency, as would be caused by heterozygous loss-of-function (LoF) mutations or genomic deletions, would cause neurological disease in humans as well. The Exome Aggregation Consortium (ExAC) database (Lek et al., 2016) gives a probability of LoF intolerance (pLI) of 1.00 and a missense constraint metric (MCM) score of 4.59 for PUM1, which further suggests that LoF of the gene could be pathogenic in humans. Here, we describe fifteen individuals with either severe early-onset disease due to complete loss of one PUM1 allele or milder, late-onset disease with partial loss of function in one PUM1 allele. These data not only demonstrate the importance of PUM1 for human neurological development and function, but also suggest that the class of RBPs should be investigated for involvement in neurodegenerative and neurodevelopmental disorders.
RESULTS

PUM1 Deletions Are Associated with Syndromic Developmental Delay
We sought patients with copy-number variations (CNVs) of PUM1 from public databases and from a cohort of 52,000 patients who underwent clinical chromosome microarray analyses for neurodevelopmental disorders (see STAR Methods for more details). We found no duplication events spanning PUM1 in affected individuals or PUM1-spanning chromosomal deletions among 41,345 healthy controls (p = 0.0092, one-tailed Chi square test without Yates correction; see STAR Methods), but we did identify 9 patients with heterozygous deletions ranging in size from 0.6 to 5.60 Mb, where the minimal region of overlap included only PUM1 ( Figure 1A ).
All nine subjects were documented to have developmental delay; eight had language delay, seven have intellectual disability, six have ataxia, and three were noted to have seizures (Tables 1 and S1 ). Much more comprehensive information was available for subject 9, who had been previously reported as having a microdeletion of 1p35.2 (Wilson et al., 2015) (Table S1 ).
To evaluate all the genes encompassed by the nine deletions and assess the likelihood of PUM1 pathogenicity, we interrogated the ExAC database again and used three additional tools: pcGERP (Petrovski et al., 2015) , EvoTol (Rackham et al., 2015) , and residual variation intolerance score (RVIS) (Petrovski et al., 2013) . Out of all the deleted genes, PUM1 had the highest probability to be pathogenic (Table S2) .
We also interrogated three databases for phenotypic associations: Online Mendelian Inheritance in Man (OMIM, https://www. omim.org/), Mouse Genome Informatics (MGI) Eppig et al., 2017) , and DisGeNET (a platform integrating information on gene-disease association from several public data sources and literature) (Piñ ero et al., 2017) . A genomewide association study cited in DisGeNET suggested that FABP3 may be associated with intellectual disability and schizophrenia (Table S2) , but the deletion in subject 4, who is noted to have an intellectual disability, does not include this gene (Figure 1A) . No other genes in the deleted regions have been associated with neurodevelopmental abnormalities (Table S2) , and the minimal shared deletion includes only PUM1.
Because none of the deletions included only PUM1, however, and the deletion of multiple genes at once can have an additive effect beyond the direct activities of any single gene, we searched for additional patients with mutations in this gene.
Severe PUM1 Missense Mutations Are Also Associated with Syndromic Developmental Delay We soon identified two individuals (subjects 10 and 11) with different de novo missense variants in PUM1 with earlyonset ataxia and developmental delay (Figures 1B and 1D and  Tables 1 and S1 ).
Subject 10 is a 9-year-old girl who was born small for her age and remained so (she is currently in the 5th centile). She manifested chorea, gait ataxia, and fine-motor incoordination by the age of 5 years (Table 1 and Movie S1). She has dysarthria and spasticity upon waking that improve over the course of the day. Magnetic resonance imaging (MRI) of the brain revealed no brain malformations (Figure 2 ) at the age of 6 years. Wholeexome sequencing of this subject and her parents revealed a heterozygous de novo substitution from arginine 1139 to tryptophan, Chr1(GRCh37):g31409510 G>A (p.Arg1139Trp, transcript NM_001020658.1), in the highly conserved RNA-binding PUM-HD (Zamore et al., 1997) . This amino acid change is located in the eighth repeat of the PUM-HD ( Figures 1B, 1D and S1A). The p.Arg1139Trp variant was not found in the ExAC database or in BRAVO, a whole-genome sequencing consortium that include functional variants for 62,785 healthy individuals (https://bravo.sph.umich.edu/freeze5/hg38/). Therefore, this is not a common benign variant. Moreover, p.Arg1139Trp is a nonconservative amino acid substitution; because these residues differ in polarity, charge, and size, the mutation is likely to affect secondary protein structure. The in silico predictors SIFT (Kumar et al., 2009 ) and PolyPhen2 (Adzhubei et al., 2010) indicate this variant should be pathogenic (Table S1 ). This subject also harbored a de novo nonsense variant of uncertain significance in the XPR1 gene, in which missense variants have been implicated in late-onset primary familial brain calcification (PFBC) (Anheim et al., 2016; Legati et al., 2015; Moura and Oliveira, 2015) . Subject 10 had congenital, not late-onset, disease, but only time will tell if she develops PFBC later in life.
Subject 11 is a 9-year-old girl who developed generalized epilepsy starting at the age of 5 months that worsened over time. The seizures were not controllable by polypharmacy (carbamazepine, phenobarbitone, lamotrigine, levetiracetum, clobazam, oxcarbazepine, cannabidiol, and combinations) or the ketogenic diet; her electroencephalogram (EEG) findings were consistent with infantile-onset epileptic encephalopathy (Table 1 and Figure S2 ). She developed early-onset, progressive ataxia with hypotonicity in her lower limbs (Table 1 and Locations of the PUM1 mutations in subjects 10 and 11 and family X are indicated. (C) Pedigree shows autosomal dominant inheritance of adult-onset ataxia in family X. White and black denote unaffected and affected individuals, respectively; squares indicate males and circles indicate females; diamonds and numbers indicate the respective offspring; a line through the box indicates that the individual is deceased. Subjects 12-18, who have been sequenced, are numbered in the order in which they were identified; DNA was not available from affected individuals without a subject number. Subject 17 (asterisk) carries the familial mutation but does not have reported ataxia. The square box with dots (the great-grandfather of the proband) is a deceased individual who began using a walker in his 30s or 40s. The red arrow indicates the proband (subject 12). (D) Protein alignment and comparison of the affected PUM1 residues compared to 21 organisms from human to Drosophila melanogaster. Different colors highlight degree of conservation: yellow for full conservation, light blue if conserved in all but one organism, and gray if more than one organism does not share the same amino acid. The human PUM1 amino acid sequence is used here as the reference protein.
See also Figure S1 and Tables S1, S2, and S3. Clinical information on subjects 1-8 was taken from clinical databases (see STAR Methods for more detail). Mb, megabase; nt, nucleotide; -, not known. R, arginine; W, tryptophan; S, serine; T, threonine. Subj., subject; AD, autosomal dominant inheritance.See also Tables S1 and S3 and Movies S1, S2, S3, and S4. a Subject 9's clinical details were obtained from Wilson BT., et al., 2015 (Wilson et al., 2015 and Decipher (Firth et al., 2009 ).
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). In addition, she suffers global developmental delay, cortical visual impairment, stereotypic hand-clasping, scoliosis, facial dysmorphia, and low bone mineral density in the neck of femur (four standard deviations below normal for age) (Tables 1 and  S1 ). MRI revealed an enlarged fourth ventricle with elevation and shortening of the cerebellar vermis ( Figure 2 ). Recently, she has been noted to have mild idiopathic intracranial hypertension with bilateral papilledema that improves with lumbar punctures. She was enrolled with her parents in a trio exomesequencing project (Figures S1B and S1C) and was found to be heterozygous for a de novo missense variant adjacent to the eighth PUM-HD repeat just outside the PUM-HD region, Chr1(GRCh37):g31406186 G>A, a nonconservative amino acid substitution from arginine 1147 to tryptophan (p.Arg1147Trp, transcript NM_001020658.1) ( Figures 1B and 1D ). This variant affects a highly conserved residue and was not present in ExAC or BRAVO; it is predicted to be pathogenic by SIFT and PolyPhen2 (Table S1 ). Based on the phenotype of subjects 10 and 11 and the areas of overlap with subjects 1-9, we refer to this disease as Pumilio1-associated developmental disability, ataxia, and seizure syndrome (PADDAS).
A PUM1 Missense Mutation Associated with AdultOnset Ataxia A rare missense variant was identified in PUM1 in a family with cerebellar ataxia (family X) ( Figure 1C and Table 1 ). Previous testing in this family had ruled out triplet repeat expansions in SCA 1, 2, 3, 6, 7, 8, and 17. Exome sequencing identified a heterozygous missense variant, Chr1(GRCh37):g.31414862 T>A, resulting in an amino acid change from threonine 1035 to serine (p.Thr1035Ser, transcript NM_001020658.1) located within PUM1-HD 6 ( Figures 1C, 1D , S1D, and S1E) in two affected sisters (subjects 12 and 13) but not their unaffected mother (subject 16); this finding was confirmed by Sanger sequencing. Segregation analysis using Sanger sequencing of DNA from the third affected sister (subject 14), her affected, deceased father (subject 15), and his 80-year-old sister (subject 17, who carries the variant but is reported to be unaffected) and brother (subject 18, who does not carry the variant and is reported to be unaffected) indicates an autosomal-dominant mode of inheritance with incomplete penetrance. We refer to this condition as adultonset syndrome Pumilio1-related cerebellar ataxia (PRCA).
Subjects 12, 13, and 14 are currently 59, 58, and 52 years of age, respectively ( Figure 1C and Table 1) , and developed an adult-onset, slowly progressive cerebellar ataxia in their 30s or 40s; MRI studies of subjects 12 and 13 at 50 and 58 years of age, respectively (Figure 2 ), revealed mild vermian atrophy compared to normal MRI images taken 8 and 11 years previously. Their father, subject 15, developed ataxia in his 50s and died at the age of 81 years. Subject 15's uncles, as well as his own father, were reported by the family to have adult-onset ataxia and needed walkers, but there is no available clinical documentation on these individuals. The cerebellar degeneration in the affected members of family X is (or was) characterized by gait ataxia, dysmetria, dysarthria, and in some cases, diplopia (Tables 1 and S3 ; see also Movie S3 for subject 12 and Movie S4 for subject 13). The affected individuals have no co-morbidities. Thr1035 is highly conserved, and interestingly, the family's Thr1035Ser variant appeared once among 121,296 alleles (i.e., 60,706 unrelated individuals without neurological disease) in the ExAC database (8.244eÀ06), but not in BRAVO. Given the late onset of the disease, this single individual does not necessarily present counterevidence to the pathogenicity of the mutation, since someone who contributes to the database when apparently healthy could develop disease later in life (Tarailo-Graovac et al., 2017) ; this individual might, alternatively, be nonpenetrant. Moreover, that the same mutation could present symptoms in an individual as early as their 30s or as late as their 50s suggests that there are factors that influence penetrance.
The PUM1 Missense Mutations Diminish PUM1 Protein Stability and Increase Levels of PUM1 Targets To evaluate the molecular effects of the identified missense mutations, we sought cell lines from patients. We were able to obtain a cultured fibroblast cell line from subject 11 (early-onset PADDAS) and lymphoblastoid cells from subjects 12 and 13 (adult-onset PRCA).
The R1147W mutation (subject 11, juvenile-onset disease) appears to markedly reduce PUM1 protein stability. Western blot analysis showed that, compared with fibroblast cell lines from three age-matched control individuals, subject 11's fibroblasts had only $43% of WT PUM1 levels. Protein levels of ATXN1 and E2F3, two well-known PUM1 targets (Gennarino et al., 2015b; Miles et al., 2012) , were elevated in these cells by $51% and $66%, respectively (Figures 3A, 3B, and S3). PUM1 mRNA levels showed no change, but the mRNA levels of ATXN1, E2F3, and the four other known PUM1 targets-CDKN1B (Kedde et al., 2010), SAE1, CDK1, and AAMP (Chen et al., 2012) -were all elevated ( Figure 3B [right panel]). FEV mRNA that does not have a PUM1 binding site in its 3 0 UTR was used as a negative control ( Figure 3B ).
The T1035S variant (family X, adult-onset disease) reduced PUM1 stability to a lesser degree. Western blot analysis of lymphoblastoid cells from subjects 12 and 13 and three agematched controls showed PUM1 levels to be $73% (subject 12) and $74% (subject 13) of WT levels ( Figure 3C ). The consequent increase in ATXN1 protein levels in subject 12 was $49% and in subject 13 was $53%; E2F3 levels rose by $41% and $43% in the two subjects, respectively ( Figure 3D ). Again, PUM1 mRNA levels were unaffected, but mRNA levels of PUM1 targets were elevated ( Figure 3D [right panel]). (Note that lymphoblastoid cells do not express CDK1, so this factor could not be compared.)
Evolutionary Action Algorithm Predicts Loss of Fitness for Each Missense Mutant
We could not obtain consent from the family of subject 10 (R1139W) to collect cells, but we were able to apply the evolutionary action (EA) algorithm, which uses homology and phylogeny to estimate the overall loss of fitness to an organism likely to be caused by a missense variant (Katsonis and Lichtarge, 2014, 2017) . The higher the EA score, on a continuous scale from 0 to 100, the greater the perturbation of protein function and loss of organismal fitness. Among the three variants, R1147W produced the largest EA score (81); R1139W had an EA score almost as high (70), and T1035S (family X) had the lowest EA score (32; see Table S1 ). These EA scores thus correspond very nicely with the different phenotypic severities we see resulting from these mutations. Applying a simple linear equation to the relative difference in EA scores between R1147W and T1035S (see STAR Methods), we can predict the degree to which these mutations reduce PUM1 protein levels. Taking the observed 55% reduction in levels for p.Arg1147Trp as a starting point, the equation predicts that T1035S would reduce PUM1 levels by 22%, which is quite close to the actual average reduction of 25% we found in the cell lines from subjects 12 and 13. The same equation predicts that R1139W would cause a reduction in protein levels of 48% (Table S1 ).
PUM1 Variants Are Impaired in Their Repression Activity
We next performed in vitro transfection assays with WT and mutant PUM1 variants at different concentrations to evaluate their ability to inhibit transcription of ATXN1 and E2F3 in HEK293T cells. As expected, overexpression of WT PUM1 at different concentrations reduced the protein and mRNA levels of both ATXN1 and E2F3 compared to cells transfected with an empty vector (Figures 4A, 4B, . Given that the R1147W mutation markedly reduced PUM1 protein levels, we suspected that strongly overexpressing this mutant might enable it to function, and indeed this was the case: overexpression of PUM1 p.Arg1147Trp reduced ATXN1 and E2F3 levels. On the other hand, overexpression was insufficient to overcome the defects of R1139W and T1035S within the PUM-HD (RNA-binding) domain ( Figures 4A, 4B , and S4A-S4C).
Elevated levels of PUM1 alter the morphology of induced pluripotent stem cell (iPSC)-derived neurons, most notably by reducing dendritic arborization (Rodrigues et al., 2016) . To test whether overexpressing PUM1 mutants recapitulates this abnormal morphology, and thus to gauge how much function they retain, we evaluated dissociated mouse hippocampal quantification of PUM1 and its targets in fibroblasts from subject 11 compared to three age-matched fibroblast control cell lines. FEV, which does not have PUM1 binding sites in its 3 0 UTR, served as a negative control.
(C and D) (C) Representative western blot and (D) (left) quantification of PUM1 and its targets in patient-derived lymphoblastoid cell lines from subjects 12 and 13 (late-onset ataxia), compared to three age-matched lymphoblastoid control cell lines, showing a PUM1 decrease of about 25%. (Right) quantification of mRNA of PUM1 and its targets in patient-derived lymphoblasts from subjects 12 and 13 compared to three age-matched lymphoblast controls. FEV again served as a negative control. All experiments were performed six times, blinded to genotype (data represent mean ± SEM). Data were normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) protein or mRNA levels as appropriate. p values were calculated by Student's t test; *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S3 for human ATXN1 antibody validation.
neurons. After confirming that either 3xHA-PUM1 WT or the mutants were all localized at the cell body of hippocampal neurons, we overexpressed the same amount of 3xHA WT or mutant PUM1 in hippocampal neurons and measured dendritic complexity ( Figure S4D ). Sholl analysis showed that, as expected, overexpression of WT PUM1 in neurons to about twice normal levels impaired dendritic branching ( Figure 4C ). Overexpression of each mutant suppressed dendritic arborization somewhat compared to empty vector, particularly between 50 and 130 mm from the soma, but only T1035S approached the degree of suppression seen with WT PUM1 ( Figure 4C ). This is consistent with the milder deficits in family X and suggests that PUM1 may have other functions independent of RNA binding (Darnell and Richter, 2012) .
Patients with a $50% reduction in PUM1 protein levels (subjects 1-11) developed a phenotype very similar to that of Pum1 knockout mice (Gennarino et al., 2015b ). These mice not only have hyperactivity (noted in a few of the PADDAS patients) and progressive cerebellar signs involving gross and fine motor incoordination, but they also show marked growth defects and spontaneous seizures at 16 weeks of age; those that survive gestation (they are born at a lower frequency than expected for Mendelian ratios) are smaller than normal at birth and fall farther behind on the growth curve over the course of their lives (Gennarino et al., 2015b) . As noted in Table S1 , many of the PADDAS subjectsparticularly the two missense mutation patients, for whom we have the most reliable clinical data-are small for their age. The two male subjects have cryptorchidism, which is consistent with the testicular hypoplasia reported in Pum1 knockout mice (Chen et al., 2012) . These patients are not null for PUM1, however, so we re-examined the phenotype of our Pum1 haploinsufficient mice, which we had reported as having progressive ataxia, hyperactivity, and Purkinje cell degeneration (Gennarino et al., 2015b) .
We found that 11 out of 16 (69%) heterozygous Pum1 +/À mice exhibited spontaneous seizures by the end of the 30th week of age ( Figure 5A and Movie S5) and showed abnormal EEG activity with generalized epileptiform spikes, indicating a state of subclinical seizures, by the age of 16 weeks ( Figure 5B ). We performed cresyl violet staining (Nissl staining) on cerebella from WT, Pum1
, and Pum1 À/À mice at 5 weeks of age and found that Pum1 À/À mice have smaller-than-normal cerebella (Figure 5C ). These two Pum1 mutant lines are therefore a reliable model of PUM1 haploinsufficiency in humans.
DISCUSSION
The identification of these patients supports our initial hypothesis that PUM1 would prove to be involved in human neurological disease. The difference PUM1 protein levels make in these individuals is striking: subject 11, with $45% of normal PUM1 levels, developed severe disease in infancy, whereas members of family X, who retained $75% of normal PUM1 levels, developed a very mild ataxia in adulthood. Both missense mutations, however, failed to properly suppress PUM1's six known targets, whose protein and mRNA levels were significantly elevated. Even as we strive to identify the full complement of PUM1 targets, it will be useful to understand the particular roles these six proteins play in the developing brain. ATXN1 and E2F3 may prove particularly challenging, as both are involved in transcription: ATXN1 is a transcriptional suppressor, whereas E2F3 is an activator, particularly of genes with functions in cellular proliferation and differentiation (Chong et al., 2009) . Each influences the expression of multiple targets, many of which have yet to be identified. The other PUM1 targets are involved in protein metabolism (SAE1, sumoylation), angiogenesis (AAMP), or cell-cycle regulation (CDKN1B and CDK1). In this context, it is worth noting that PUM1 has a close homolog, PUM2, which has been shown to affect neurological development and function in the rat (Darnell and Richter, 2012; Vessey et al., 2006 Vessey et al., , 2010 and, most recently, in the mouse (Zhang et al., 2017) .
The mutations resulting in infantile disease were not identified in the ExAC database (release version: August 8, 2016) (Lek et al., 2016) , but the mutation associated with adult-onset disease was found in one exome from ExAC. This could reflect the milder, later onset of the disorder associated with this variant: the individual in ExAC provided his or her clinical information only once, and it remains to be seen if s/he will develop ataxia in later life or if s/he represents a case of incomplete penetrance.
The incomplete penetrance in family X, along with the small number of family members that we were able to directly evaluate, leads us to be cautious in making claims about the pathogenicity of the T1035S variant. T1035S did lose its ability to repress transcription of PUM1 targets in the cellular studies, and the symptoms in the adult-onset PRCA are consistent across the family, though the age of onset varied over a $20-year period. Such wide variance indicates the presence of factors modulating onset or penetrance. Subject 17 and the single individual with this variant in ExAC could also be resilient individuals in the face of this milder mutation (Tarailo-Graovac et al., 2017) . Further studies will be necessary to understand what other molecular or environmental factors confer risk for (or protection against) PRCA. It would be very interesting to determine whether variations in polyglutamine tract length in ATXN1 or other proteins are risk factors for PRCA, as for example has been shown for ATXN1, ATXN2, and amyotrophic lateral sclerosis (Conforti et al., 2012) . Ultimately, we must await the identification of other mild variants in unrelated individuals with adult-onset ataxia to confirm the contribution of PUM1 to a late-onset ataxia. Genes encoding RBPs are increasingly appreciated as potential causes of disease (Cookson, 2017) . Given that RBPs regulate hundreds or thousands of mRNAs, it is conceivable that alterations or mutations in RBPs will be at the root of many complex neurological diseases (Gerstberger et al., 2014; Lukong et al., 2008) . The identification of factors that regulate the levels of disease-driving proteins, particularly those whose excess or insufficiency are detrimental to neurons (such as APP and SNCA), would be a reasonable place to start. Besides deepening our understanding of pathogenesis, there is a strong likelihood that such studies would also reveal new candidate disease genes, as with the discovery of ATXN1's regulation by PUM1. Understanding RBPs and their associated pathways could also lead to molecular means of modulating protein levels in neurological disorders in which protein accumulation is central to pathogenesis.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
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Zogopoulos, G., Ha, K.C., Naqib, F., Moore, S., Kim, H., Montpetit, A., Robidoux, F., Laflamme, P., Cotterchio, M., Greenwood, C., et al. (2007) . Germline DNA copy number variation frequencies in a large North American population. Hum. Genet. 122, 345-353. platform (https://gemini.readthedocs.io/en/latest/), incorporating data from the NCBI database (dbSNP, version 138), the 1000 Genomes Project (release date 21/05/2011), and the NHLBI Exome Sequencing Project Exome Variant Server (EVS) database (ESP6500SI-V2; http://evs.gs.washington.edu/EVS/), and the Combined Annotation Dependent Depletion database (CADD, http://cadd.gs.washington.edu/). Variants were filtered out if they were in dbSNP, had a frequency of > 1% in both 1000 Genomes and EVS, were present in an in-house control, or were predicted to have a low impact on protein function. Any candidate variants from prioritization were further assessed for pathogenicity using in silico prediction tools-SIFT, PolyPhen2, PROVEAN (Choi et al., 2012) , and CADD-and were manually checked on the Binary Alignment Map files through Integrative Genomic Viewer (IGV) (Thorvaldsdó ttir et al., 2013; Palmer et al., 2015) . Informed consent for exome sequencing was obtained and the research was approved by the ethics committee from The Sydney Children's Hospital Network and the Prince of Wales Hospital Campus, Sydney, Australia (HREC ref no 13/094 and LNR/13/SCHN/112). Subjects 12, 13, and 16: Exome sequencing was performed on blood-derived DNA. Exome target enrichment was performed using the Sure Select All Exon V5 capture kit, followed by sequencing on the Illumina HiSeq 2000. Reads were quality trimmed and subsequently aligned to hg19 using BWA. Duplicate reads were marked and excluded using Picard (http://picard.sourceforge.net). Average coverage of the consensus coding sequence was calculated using Genome Analysis ToolKit (GATK, https://software. broadinstitute.org/gatk/). Mean coverage was approximately 130x for Subjects 12 and 13 after duplicate read removal and 89x for Subject 16. Variant calling and annotation was performed with GATK, Sequence Alignment/Map Tools (SAMtools, http:// samtools.sourceforge.net/) and BCFtools (https://samtools.github.io/bcftools/) (Beaulieu et al., 2014) . The data were filtered to identify missense, nonsense and splice variants. These were screened against variants in ExAC (http://exac.broadinstitute.org/), the NHLBI Exome Sequencing Project Exome Variant Server (EVS, http://evs.gs.washington.edu/EVS/), the NCBI database (dbSNP, https://www.ncbi.nlm.nih.gov/snp/), and in-house variant databases (Care4Rare, CHEO Research Institute, Ottawa, Ontario, Canada). In addition, only variants shared by Subjects 12 and 13 were considered; variants inherited from the unaffected mother (Subject 16) were filtered out. Sanger sequencing of the PUM1 variant was performed on available DNA from Subjects 12-18.
In vivo animal studies All animal procedures were approved by the Institutional Animal Care and Use Committee for Baylor College of Medicine and Affiliates. Mice were maintained on a 12-hr light, 12-hr dark cycle with regular mouse chow and water ad libitum. Pum1 mutant mice used here were previously generated in a B6/129 mixed background by the University of Connecticut Gene Targeting and Transgenic Facility (Chen et al., 2012) . For the experiments in Figure 5 we used 16 mice per genotype (8 males and 8 females) from 18 to 38 weeks of age for panel A; 4 mice per genotype for panel B (2 males and 2 females); and 6 mice per genotype for panel C (3 males and 3 females).
Fibroblast generation and culturing
Primary fibroblasts were isolated from a skin biopsies taken from Subject 11 (9-year old female) and three age-matched controls using standard methodology (Barch and Association of Cytogenetic Technologists, 1991) , and placed in a transport medium (Ham's F10, Thermo Fisher Scientific). The skin tissue specimen was later removed from the transport medium using a sterile technique (in a Class II biohazard cabinet) and transferred to a sterile Petri dish where it was cut into small pieces (< 0.5 mm) using sterile scalpel blades. These pieces were later transferred to a lower surface of a 25 cm 2 culture flask (6-8 pieces per flask) which had been pre-moistened with 1-2 mL of AmnioMAX Complete Medium (Thermo Fisher Scientific) supplemented with 1% penicillin/streptomycin. Cell cultures were maintained at 37 C in a humidified incubator supplemented with 5% CO 2 . When cell growth was observed around the edges of the tissue, usually 3 to 5 days later, 2 to 3 mL were added. Once growth was established and the tissue was anchored to the flask, another 8 mL of AmnioMAX Complete Medium was added. Thereafter, the medium was renewed every 3 to 4 days until ready for sub-culturing.
Lymphoblastoid cell culture Venous blood of Subjects 12 (59-year old female), 13 (58-year old female), and three age-matched controls was drawn into ACD solution A tubes. Buffy coat was prepared, lymphocytes were pelleted and transformed with Epstein-Barr virus and cyclosporin A following standard procedures. Cell lines were grown in RPMI 1640 medium (Invitrogen, Carlsbad, CA) supplemented with 10% heat-inactivated fetal bovine serum (Atlanta Biological, Flowery Branch, GA) and 1% penicillin/streptomycin. Cell cultures were maintained at 37 C in a humidified incubator supplemented with 5% CO 2 . Medium was renewed every 2 to 3 days to maintain the cell density between 1 3 10 5 and 2 3 10 6 cells/ml. Subjects 12 and 13 consented to participate in the Care4Rare Canada research protocol as described above.
Cell culture, transfection and mutagenesis Human embryonic kidney immortalized 293 cells (HEK293T) and human medulloblastoma cells (DAOY) were grown in DMEM (Invitrogen), supplemented with 10% of heat-inactivated fetal bovine serum (FBS) and 1% penicillin/streptomycin. All cells were incubated at 37 C in a humidified chamber supplemented with 5% CO 2 . Transfection of HEK293T cells was performed using jetPRIME 
METHOD DETAILS
In silico variant impact prediction The three missense mutations were assessed for their likely effect on protein function using SIFT, PolyPhen2, and Evolutionary Action (EA) (Katsonis and Lichtarge, 2014, 2017) . EA scores were also used to predict the percent reduction of protein levels for pArg1139Trp, according to the equation
Protein quantification and western blot analysis Lymphoblastoid or fibroblast cell suspension and HEK293T cell cultures were collected at 6 3 10 6 confluence and processed for
Primary hippocampal neuron culture, transfection and immunostaining Hippocampal neurons were prepared each of two WT postnatal day 0-1 FVB/N mice. Cells from each mouse were plated independently on poly-D-lysine/mouse laminin-coated coverslips (BD Biosciences, Franklin Lakes, NJ) in Neurobasal medium supplemented with GlutaMAX (Invitrogen), B-27 and 1% FBS. At days in vitro (DIV) 9, neurons were transfected with 300ng pEGFP-C1 plus either 700ng empty vector or vectors expressing 3xHA-PUM1 variants. At DIV 14, neurons were fixed with 4% formaldehyde/4% sucrose in PBS, and permeabilized/blocked by 2% goat serum and 0.1% Triton X-100 in PBS (blocking buffer). Samples were then stained with anti-GFP antibody (Abcam, ab13970) and anti-HA. 11 antibody (901514 [Biolegend, San Diego, CA]) at 4 C overnight, then secondary Alexa-conjugated antibodies at room temperature for 1hr. Z stack images were acquired by LSM710 (Zeiss, Oberkochen, Germany) confocal microscope under the same parameter settings. Neurons were traced and Sholl analysis was performed using Neurolucida 360 (MBF Bioscience, Williston, VT) in a blinded manner. This experiment was performed in triplicate for each mouse. 3xHA-PUM1 WT and variants were all localized at the cell body of hippocampal neurons. The overexpression level for each variant was quantified based on the fluorescence signal intensity of the HA tag. Specifically, cells expressing 3xHA-PUM1 were identified and analyzed using Imaris (http://www.bitplane.com/download); the mean intensity of HA at the cell body was used to quantify PUM1 overexpression for each variant.
Surgery and EEG recordings
The methods were modified from previous publication (Hao et al., 2015) . Adult mice at 12 weeks of age were anesthetized with 1%-2% isofluorane. Under aseptic conditions, each animal was surgically implanted with cortical EEG recording electrodes (Teflon-coated silver wire, 127 mm diameter) in the subdural space of the left parietal cortex and left frontal cortex, respectively, with the reference electrode positioned in the occipital region of the skull. The third recording electrode (Teflon-coated tungsten wire, 50 mm diameter) was aimed at the dentate gyrus (P2.0R1.8H1.8) with the reference electrode at the corpus callosum. All electrode wires were attached to a miniature connector (Harwin Connector, Nicomatic, Warminster, PA) and secured on the skull by dental cement. After 2 weeks of post-surgical recovery, simultaneous EEG activity (filtered between 0.1 Hz and 1.0 kHz, sampled at 2 kHz), and behavior were recorded in freely-moving mice for a total of 28 hours over 7 days.
Cresyl Violet (Nissl) staining Serial paraffin sagittal sections (40 mm) from WT, Pum1 +/À and Pum1 À/À mice at 5 weeks of age were cut on a cryostat, then collected and processed free-floating in PBS. Free-floating tissue sections were washed with PBD and Nissl-stained in a solution containing 0.1% thionin in acetic acid, pH 5.5. Four mice (2 males and 2 females) were used for each genotype, for a total of 12 mice.
Primers
In order to unambiguously distinguish spliced cDNA from genomic DNA contamination, specific exon primers were designed to amplify across introns of the genes tested. The primers for all target genes tested were designed with Primer3 (Koressaar and Remm, 2007; Untergasser et al., 2012) . See Key Resources Table for primer sequences.
Experimental design
For protein and RNA quantification from patient-derived cell lines, we used values from six independent experiments with three biological replicates for each experiment. At every stage of the study, for each experiment, the experimenter was blinded to the identity of control and patient-derived cell lines. For example, for the data in Figure 3 , Experimenter #1 made a list of samples and controls to be tested, Experimenter #2 randomized this list and re-labeled the tubes; this was the only person who knew the key to identify the samples. These samples were then distributed to Experimenter #3 to culture the cells, then to Experimenter #1 to perform western blots and qRT-PCRs, and lastly Experimenters #1 and #4 analyzed the data. Only then was the key applied to identify the samples.
For mouse experiments, we used equal numbers of male and female animals. The experimenters as noted above were randomized and blinded for performing the experiments, doing statistical analysis, and interpreting the results.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical significance was analyzed using GraphPad Prism Software. All data are presented as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.0001 in all figures.
The range of expression levels in qPCR was determined from six independent experiments with three biological replicates by calculating the standard deviation of the DCt (Pfaffl, 2001) . We considered genes to be down-or upregulated if they showed a change in their expression with a p value less than < 0.01.
The range of expression levels in western blots was determined from six independent experiments with three biological replicates. P values were calculated by Student's t test or analysis of variance with Tukey's post hoc analysis.
For the Sholl analysis, data represent mean ± SEM from 38-44 neurons in each of three transfections. Statistical analysis was performed by two-way ANOVA with Tukey's multiple comparisons test.
The number of animals used (n), and the specific statistical tests used are indicated for each experiment in the figure legends. Sample size was based on previous experience using the same mice (Gennarino et al., 2015b) . Mice were randomly assigned to vehicle or treatment groups using Excel software to generate a table of random numbers, and the experimenter was always blinded to the treatment.
DATA AND SOFTWARE AVAILABILITY
No software was generated for this project. All software used in this study is publicly available and links are provided as appropriate in different sections of the methods.
Cell 172 The purified monoclonal antibody #534 was confirmed to react with purified human ATXN1 (lane 1) and human ATXN1 expressed in DAOY cells (lane 4 and 5). Furthermore, a reduction in signal is observed when human ATXN1 is knocked down in DAOY cells upon treatment with a small interfering RNA against ATXN1 (siATXN1). There was no signal observed from mouse brain lysate (lanes 2 and 3), indicating that the purified antibody specifically recognized human ATXN1. (A-C) Quantification of (A) PUM1, (B) ATXN1, and (C) E2F3 protein levels, see Figure 4A for corresponding western blots. All the experiments were performed in triplicate (data represent mean ± SEM); p values were calculated by Student's t test; *p < 0.05, **p < 0.01, ***p < 0.0001. Data were normalized to GAPDH protein levels. (D) Left panel: Representative pictures of 3xHA-PUM1 localization in hippocampal neurons. Right panel: Quantification of PUM1 overexpression in hippocampal neurons shows that 3xHA-PUM1 WT and mutants were all transfected at the same level. Data represent mean ± SEM from 38-44 neurons for 3 independent animals per transfection. Statistical analysis was performed by two-way anova with Turkey's multiple comparisons test. ns, not statistically significant.
